Estimated 2026 sales: $29.81 billion
2019 sales: $20.09 billion
2019-26 CAGR: 5.8%
Faced with an aging drug portfolio in recent years, Eli Lilly has made strides in refocusing around new drugs. Now, the company says it’s positioned for “top-tier” growth in the coming years.
Evalaute’s growth rankings bear out that prediction. Analysts predict the company will generate 5.8% annual average growth through 2026, besting all but three biopharma companies on the list.
The stretch of expected growth comes after some tough losses of exclusivity for Eli Lilly, including its blockbuster erectile dysfunction drug Cialis. And it comes after a big restructuring implemented by CEO Dave Ricks in 2017, under which the company cut 3,500 jobs to focus on new drugs.
Looking forward, the company will lean on several new launches that have been posting strong growth in recent quarters, including Type 2 diabetes med Trulicity, immunology drug Taltz, migraine-fighter Emgality and more.
In fact, Lilly drugs approved since 2014 made up 51% of the company’s total sales in the first quarter of 2020. That marks a turnabout for the company from prior years, when it was mostly reliant on old drugs, Evaluate pointed out earlier this year. Five years ago, 95% of Lilly’s sales came from elderly products.
Meanwhile, Lilly has also inked some buyouts to bolster its pipeline and marketed portfolio. The company started 2019 with its $8 billion buyout of Loxo Oncology, getting its hands on Bayer-partnered cancer med Vitrakvi and other pipeline candidates. Lilly has since offloaded those drug rights to Bayer and scored an approval for first-in-class cancer drug Retevmo.
The drugmaker then kicked off 2020 with its $1.1 billion buyout of Dermira. Through that deal, the company scored Qbrexza for excessive underarm sweating, plus a phase 3 atopic dermatitis drug, lebrikizumab, and other pipeline meds.
Lilly's recent FDA approvals include migraine prevention drug Emgality, which has been scooping up share in the CGRP field despite a third-to-market approval, and the acute migraine treatment Reyvow. The meds are part of a migraine and pain franchise that Eli Lilly has been building out that will also include the Pfizer-partnered pain drug tanezumab, should it win an approval.